What was studied?
Fasting samples from two randomized phase 2 trials underwent exploratory lipidomic and metabolomic analyses.
What did the researchers report?
Retatrutide was associated with changes in metabolite clusters related to fatty-acid oxidation and insulin resistance. Patterns were observed in participants with and without diabetes.
What are the limits?
These are post hoc biomarker analyses of existing trials, not independent efficacy trials. Statistical mediation does not prove a mechanism or demonstrate fewer cardiovascular events.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.